Core Insights - Viatris Inc. is a global healthcare company with a market cap of $12 billion, focusing on affordable medicines across various therapeutic areas [1] - The company's stock has significantly underperformed the broader market, declining 9.4% over the past year compared to a 19.6% gain in the S&P 500 Index [2] - Viatris announced the acquisition of Aculys Pharma, which will enhance its CNS portfolio with two neurological treatments, targeting regulatory approval in Japan by late 2025 [4] Financial Performance - Analysts expect Viatris' EPS to decline by 12.8% to $2.31 for the current fiscal year ending in December [5] - The company's earnings surprise history is mixed, with three beats and one miss in the last four quarters [5] Analyst Ratings - The consensus rating for Viatris stock is a "Hold," based on two "Strong Buy" ratings, six "Holds," and one "Moderate Sell" [5] - Truist Financial initiated coverage with a "Buy" rating and a $15 price target, citing confidence in the company's strategic shift and promising pipeline [7]

Group 1 - Viatris Inc. has completed the acquisition of Aculys Pharma, a clinical-stage biopharmaceutical company, enhancing its growth potential [1][2] - The acquisition grants Viatris rights to develop and commercialize Pitolisant and Spydia, key assets in the Central Nervous System therapy area, along with rights for Spydia Nasal Spray in Japan and certain Asia-Pacific regions [2] - Truist initiated coverage of Viatris with a Buy rating and a $15 price target, citing positive changes under new leadership and a strong market position [3] Group 2 - Viatris is recognized as one of the best growth stocks under $25, indicating its potential for significant appreciation [1] - The company has a diverse portfolio of therapies across various therapeutic areas, which supports its market-leading position [3]